Home News General Health News USPSTF Recommends Screening for Latent TB Infection

USPSTF Recommends Screening for Latent TB Infection

Task force recommends screening asymptomatic adults at increased risk for latent TB infection

By Elana Gotkine HealthDay Reporter

TUESDAY, Nov. 22, 2022 (HealthDay News) — The U.S. Preventive Services Task Force (USPSTF) recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk. This recommendation forms the basis of a draft recommendation statement, published online Nov. 22 by the USPSTF.

Daniel E. Jonas, M.D., M.P.H., from RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center in Research Triangle Park, and colleagues reviewed the evidence on benefits and harms of screening for and treatment of LTBI for adult populations. Data were included for 113 publications (69,009 participants); 101 assessed screening test accuracy or reliability. The researchers found that no studies assessed benefits and harms of screening versus no screening. The pooled estimates for sensitivity of the tuberculin skin test were 0.80 and 0.81, respectively, at the 5-mm and 10-mm induration thresholds for positivity. At the 15-mm threshold, the pooled estimate was 0.60. For interferon-gamma release assays, the pooled estimate for sensitivity ranged from 0.81 to 0.90. For specificity of screening tests, pooled estimates ranged from 0.95 to 0.99. For treatment of LTBI, the relative risk for progression to active TB at five years was 0.35 for 24 weeks of isoniazid versus placebo; a previously published meta-analysis reported that multiple regimens were efficacious versus placebo or no treatment.

Based on these findings, the USPSTF concludes that there is moderate net benefit for preventing active TB disease by screening for LTBI in persons at increased risk for infection. Screening is recommended for asymptomatic adults at increased risk for LTBI (B recommendation).

The draft evidence review and recommendation statement have been posted for public comment. Comments can be submitted from Nov. 11 to Dec. 27, 2022.

Draft Evidence Review

Draft Recommendation Statement

Comment on Recommendation Statement

Copyright © 2022 HealthDay. All rights reserved.